Rilzabrutinib ITP denied as non-formulary by Cigna?

Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Rilzabrutinib for ITP as Non-Formulary

Cigna's formulary is the list of drugs the plan covers at a standard benefit level. When rilzabrutinib is placed on a non-covered or non-formulary tier, Cigna is saying the plan's drug benefit does not include it by default — not that the drug is ineffective or inappropriate. Non-formulary denials happen because formulary design is driven by cost negotiation and therapeutic substitution policies, not by your individual clinical circumstances.

## Why This Denial Is Appealable

Plans that cover ITP treatments at all must consider exceptions when no formulary alternative is clinically appropriate for a specific patient. Under ACA and ERISA rules, you have the right to an internal appeal and, if that fails, to external review by an independent organization. A non-formulary denial that ignores your medical history is a strong candidate for a formulary exception or medical-necessity override.

Key federal rights: - Internal appeal under ERISA §503 / ACA §2719 — the insurer must give a specific written reason and address your clinical evidence. - External review window — generally up to approximately four months from the denial; verify the exact date on your Explanation of Benefits. - Expedited review if delay would seriously jeopardize health.

## Your Appeal Process and Timeline

1. Request the formulary exception process in writing at the same time as the standard internal appeal — many plans have a parallel track. 2. Identify every formulary alternative Cigna would cover for ITP and document why each is clinically inappropriate for you (prior failure, intolerance, or a specific reason your prescriber can articulate). 3. If the internal appeal is denied, request external review without delay.

## Documentation to Gather

• Diagnosis confirmation: laboratory and clinical records establishing ITP and its severity.
• Trial-and-failure history: for each formulary alternative, chart notes or letters showing you tried it and it failed, you experienced significant adverse effects, or your prescriber documents a clinical reason it cannot be used.
• Prescriber medical-necessity letter: explains why rilzabrutinib specifically is required and why no listed formulary alternative is adequate for your case, referencing the applicable ASH guideline.
• Plan documents: the Summary Plan Description language on formulary exceptions and medical-necessity overrides.

## Criteria-Mapping Structure

Review Cigna's published formulary exception criteria alongside the FDA-approved prescribing information for rilzabrutinib. Create a column for each criterion and a column for the chart evidence that meets it. Show that the formulary alternatives are not equivalent options for your specific clinical profile. This structure prevents the reviewer from dismissing your appeal as generic.